recently developing to such and are needs. cancer expanded robust patients indications. everyone. preclinical with novel and unmet and with At good several a committed Thank that Oncternal, who afternoon, you, pipeline have advancing target cancer treatments product Rich, medical we candidates critical for product We're clinical
focused RORX like believe our one with efforts pipelines advanced on We biological this and in experience we progression. discuss of to development on targeting cancer pathways RORX, I'd first. the and and have genesis deep Our most implicated target. diverse expertise based
RORX now INN Our antibody its from cirmtuzumab, has announcing new zilovertamab will lead inhibiting we're today on. a generic name be asset, and
with zilovertamab or leukaemia Hematology updating of American from December ongoing in ibrutinib presented patients cell be in + trial will results mantle chronic our lymphoma Atlanta Meeting in with Society We Xb/X year. lymphocytic Annual of Phase clinical this the at
our to may on poster forward presentation website. on of have noticed December ASH which XX. were available based results data abstract, our the that You are today data updated presenting as interim June look we And during on in ASH
coming invented acquisition months. Our or as for as FDA pivotal ADC an NBE potential And MCL in VLS-XXX the ADC [indiscernible] Mantle Conjugate M&A the was the this in since Drug Therapeutics and now targeting utilizes by and by to is at patients target Antibody which company targeting of VelosBio oncology RORX including ongoing well. for of activity, Zilovertamab was developed visible progressing a RORX moiety known remains interactions subject with is Cell pathways Merkin the with the US on Boehringer. agree Zilovertamab are and expect study regarding registration it we VelosBio Lymphoma, design RORX originally in. increasingly space, MK-XXXX the
at UC clinical sponsored San Diego. collaborate also to continue studies We on Zilovertamab investigator two of
breast clinical combination of metastatic women enrollment. locally treatment with HERX advanced Paclitaxel, trial XB unresectable Zilovertamab with or First negative has the in a phase of for completed cancer
trial RORX Zilovertamab is clinical cell With inhibitor ongoing X to venetoclax Phase as enrolling planned. and therapy them in our refractory relapsed combination patients. Second, CLL respect BCL targeting in to with patients a clinic the and programmes, with X of continue toward advance we
For academic CDMO lead, autologous for programme, selected progress first have preclinical have IND our studies development first completing which of with enable we and with GMP the made selected to the -- have ONCT-XXX as we half in the which we of process XXXX. in CAR-T lead supporting our tremendous submission the collaborators, our IND leading institutions
partnership regarding MTAG cell we Institutes established progress of Institutet and for the in therapy our including generation Competence next cancer Centre evaluate made We cell strengthened MK the allogeneic also based with targeting with programmes. potential recently to We immunotherapies. generation cellularity RORX a development partnership Karolinska Sweden, therapies second placental Nextgen derived joining
recently formed TK-XXX. SAB act engaged potential excited We experts cell group we cell of cell healthy are may of to which also support and sparing targeting In program, Board the another tissues. selective for renowned patients that which a also field therapy as announced that the and of of while newly our ONCT-XXX tumor therapies our and advanced relatively We about cell targeting the therapy we allow to effective targeting on formally was very bring cells development to RORX the programmes designated express have therapy RORX safer faster. efforts Advisory to in industry our ternal Scientific our serve RORX
or targeted family at clinical interim week inhibitor specific Tissue the data XXXX update oncoprotein. EXX or ETS Oncology of transformation forward small of investigational Our an the Connective CTOS oral Meeting. the next to Virtual We Annual molecule Society, presentation of look
agent is to Ewing of ONCT-XXX dosing the regimen, sarcoma amount expansion Additional designed and evaluating and that over intensified time. Phase is administered X cohort increase open is an now single ONCT-XXX using enrolling patients
latest like addition to to I'd our an the introduction to provide pipeline. Now,
of cancer dual-action program. resistance that active that, Vincent to receptor GTX call prostate N-terminus have OCNT-XXX the are was believe We The and the ligand resistant those both in including receptor, and degradation expression results that causing in OCNT-XXX androgen from evidence of developed for preclinical therapies potential body as the substantial to androgen by involving of and abiraterone. With strongly as Rich by caused review turn standard-of-care We that have acquired the been ARBX. splice part reverse may need significant has in-vitro our the such of A merger prostate OCNT-XXX variants, by in over will to in-vivo current Oncternal of with candidate tumor active is University the cancer to was binding such molecule now and designated the on mechanisms, Tennessee DAARI lead receptor is receptor. to unmet enzalutamide studies as men XXXX. suggest the OCNT-XXX addition the I our domains preclinical originally models financial or in address inhibitor our as milestones. with upcoming developed androgen and of
